Drugs / Tipepidine
Tipepidine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 21 trial | ||||||
| Phase 2 | NCT01835093 | Apr → Dec 2013 | attention deficit-hyperactivity disorder | Chiba University | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT02305134 Comparator | Jun 2015 → Mar 2019 | attention deficit-hyperactivity disorder | Chiba University | Completed | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tipepidine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01835093 ↗ |
| Known as | AT 327 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899506 ↗ |
| Known as | CR-662 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899506 ↗ |
| Known as | CRJ662 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899506 ↗ |
| Known as | Tipepidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1899506 ↗ |
| Known as | Tipepidine Hibenzate | “Drug: Tipepidine Hibenzate” NCT02305134 ↗ |
| Action | Inhibit | “It is reported that tipepidine inhibits G-protein-coupled inwardly rectifying potassium (GIRK)-channel currents.” PMID 24493927 ↗ Jan 2014 |
| Modality | Small molecule | — CHEMBL1899506 ↗ |
| Route | Oral | “Ten pediatric ADHD subjects (70% male; mean age, 9.9 years; combined [inattentive and hyperactive/impulsive] subtype, n=7; inattentive subtype, n=3; hyperimpulsive subtype,...” PMID 24493927 ↗ Jan 2014 |